IBT has a plethora of reagents, assays or services based on disease targets.
During The Covid-19 Pandemic, Ibt Proved To Be An Amazing Partner For Us At Twist Bioscience. They Played A Crucial Role In Our Product Development Journey By Helping Us Produce Pseudoviruses For Different Sars-Cov-2 Variants. Not Only That, They Also Assisted Us In Screening Over 100 Vhh Antibodies And Establishing Pseudovirus Neutralization Assays With Meticulous Validation. What Really Stands Out About Ibt Is Their Collaborative Approach To Working With Their Partners. They Worked Closely With Us To Achieve Our Short Timelines, Which Was Critical For Our Success. Together, We Have Successfully Compiled High-Quality Data For Two Manuscripts, And We Couldn’t Have Done It Without Their Expertise And Dedication. Ibt’s Proactive Stance And Attention To Detail Have Been Instrumental In Our Achievements, And We Are Extremely Grateful For Their Support. We Are Excited About What The Future Holds And Look Forward To Continuing Our Fruitful Partnership With Ibt.
Working with IBT Bioservices on our pre-clinical research projects has been a very good experience. They offer solid services that cover all the bases. From beginning to end, their team was committed, knowledgeable, and professional. IBT is a reliable partner, always kept us in the loop, provided regular updates, and paid attention to the small details. We recommend IBT to anyone seeking unparalleled CRO support.
Sabin Has Established A Robust Partnership With Ibt Bioservices, Relying On Their Expertise For The Development Of Complex Reagents And Assays. As Our Collaboratio Evolved, They Seamlessly Transitioned To Supporting Our Clinical Testing Needs For Two Vaccine Trials Using Their Cell-Based Assays. Their Comprehensive Services, Including Sample Storage And Program Management, Streamline Our Processes And Enhance Efficiency. We Value Their One-Stop-Shop Approach And Nimble Problem-Solving Abilities Which Promote An Exceptionally Productive Working Relationship.
Combating the 2026 Bundibugyo Outbreak: How IBT Bioservices Accelerates Vaccine and Therapeutic Development The spring of 2026 has brought a stark reminder of the unpredictable threat posed by filoviruses. On May 16, 2026, the World Health Organization (WHO) officially designated the rapidly expanding Ebola disease outbreak caused by the Bundibugyo
[Rockville, MD, April 2025] A promising new therapeutic is being developed to address the urgent need for effective treatments for Marburg virus disease (MVD), a highly fatal viral infection. Currently, no FDA-approved medical countermeasures (MCMs) exist for the treatment of Marburg virus (MARV). A human monoclonal antibody (mAb) derived from
IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services [Maryland, January 2024] – IBT Bioservices, a renowned figure in the Biocapital region’s life sciences landscape, proudly announces its rebranding from Integrated Biotherapeutics. Effective February 2023, IBT Bioservices unveils a revitalized identity, reinforcing its commitment to excellence in Contract Research
IBT CEO Dr. M. Javad Aman will discuss the development of a multi-component toxoid vaccine for S. aureus and the regulatory challenges and opportunities when moving a product from pre-clinical to clinical stage. The live webinar scheduled for Sept. 24, 2020 will feature experts on various aspects of antimicrobial resistance
